Other News To Note
Thursday, June 16, 2011
pSivida Corp., of Watertown, Mass., amended its existing agreement with New York-based Pfizer Inc. to focus solely on a sustained-release implant for ocular hypertension and glaucoma. The product will deliver the drug latanoprost using a system based on pSivida's Durasert technology. Pfizer will pay $2.3 million initially, and pSivida will develop the glaucoma candidate through Phase II trials. At that point, Pfizer can exercise an option for $20 million to develop and commercialize the product globally. In that event, pSivida would be eligible for milestone payments worth up to $146.5 million, plus double-digit royalties.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.